Nike (NKE) Surpasses Estimates
Post# of 130
For its first quarter fiscal 2016, NKE posted revenues of $8.41 billion, a 5% increase year-over-year on a currency-neutral basis, and net income (excluding non-recurring items) of $1.18 billion, or $1.34 per diluted share, compared to net income of $962 million, or $1.09 per diluted share in the same quarter the prior year, surpassing the Capital IQ Consensus Estimate of $1.19 earnings per share on revenues of $8.22 billion.
According to NKE, the company is well-positioned to continue to deliver long-term growth that is both sustainable and profitable.
NKE is the world’s leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities.
More about Nike, Inc. (NKE) at www.nikeinc.com
**
Jabil Circuit Inc. (JBL) stock surged over 9% in the extended session Thursday after the company reported solid quarterly financial performance.
For its fourth quarter fiscal 2015, JBL posted revenue of $4.68 billion, a 15.39% increase year over year, and non-GAAP (excluding non-recurring items) net income of $103.22 million, or $0.53 per diluted share, compared to non-GAAP net income of $10.19 million, or $0.05 per diluted share, topping the Capital IQ Consensus Estimate of $0.44 earnings per share on revenues of $4.55 billion for the period
For its full year fiscal 2015, JBL generated $1.24 billion in cash flow from operations and returned approximately $150 million to shareholders via dividend and share repurchases.
According to its business outlook, JBL anticipates fiscal year 2016 revenue of approximately $20 billion and core diluted earnings per share of $2.60 for the period.
JBL is an electronic product solutions company providing comprehensive electronics design, production and product management services to global electronics and technology companies.
More about Jabil Circuit Inc. (JBL) at www.jabil.com
**
After the closing bell on Thursday, Bellerophon Therapeutics LLC (BLPH) announced positive data from an interim analysis of its Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). According to BLPH, the data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy.
BLPH also said that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for its Phase 3 PAH program for INOpulse.
BLPH's INOpulse is a proprietary pulsatile nitric oxide delivery device.
Pulmonary Arterial Hypertension is a rare, chronic and currently incurable disease that causes the walls of the arteries of the lungs to tighten and stiffen.
Shares of BLPH soared more than 80% following the announcement.
BLPH is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases.
More about Bellerophon Therapeutics LLC (BLPH) at www.bellerophon.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE WORLD ( www.crweworld.com ), a community targeted platform which goal is to be a one-stop shop for the various needs of online consumers in a range of marketing specialties like Real Estate, Coupons & Deals, Business Directory and more
CRWE WORLD’s business model is based on selling advertising to businesses targeting their marketing message locally, nationally, internationally and also to target potential clients for an specific location, such as within a certain zip code.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer